When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. PARP inhibitor - Wikipedia

   en.wikipedia.org/wiki/PARP_inhibitor

   Side effects of PARP inhibitor treatment for cancer may include neutropenia, and a risk of anaemia. [25] People who take this medication also commonly report fatigue. [ 25 ] The toxicity profile of PARP inhibitors when treating cancer has not been found to be more serious than chemotherapy agents, however, further research is needed to ...

3. Niraparib/abiraterone acetate - Wikipedia

   en.wikipedia.org/wiki/Niraparib/abiraterone_acetate

   Niraparib/abiraterone acetate, sold under the brand name Akeega, is a fixed-dose combination anti-cancer medication used for the treatment of prostate cancer. [2] It contains niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (antineoplastic agent), and abiraterone acetate, a CYP17 inhibitor (hormone antagonist).

4. Niraparib - Wikipedia

   en.wikipedia.org/wiki/Niraparib

   [3] [4] It is a PARP inhibitor. The most common side effects include nausea (feeling sick), thrombocytopenia (low blood platelet counts), tiredness and weakness, anemia (low red blood cell counts), constipation, vomiting, abdominal (belly) pain, neutropenia (low levels of neutrophils, a type of white blood cell), insomnia (difficulty sleeping ...

5. Management of prostate cancer - Wikipedia

   en.wikipedia.org/wiki/Management_of_prostate_cancer

   For men over 64 with prostate cancer limited to the pelvis, using fewer, larger doses of radiation (hypofractionation) results in similar overall survival rates. [28] The risk of dying from prostate cancer or having acute bladder side effects may be similar to that of longer radiation treatment. [28]

6. Veliparib - Wikipedia

   en.wikipedia.org/wiki/Veliparib

   Veliparib (ABT-888) [1] is a potential anti-cancer drug acting as a PARP inhibitor.It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments.

7. Olaparib - Wikipedia

   en.wikipedia.org/wiki/Olaparib

   In January 2018, olaparib was approved in the United States for the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any ...